Source: PR Newswire

Press Release: Roivant : Roivant Statement on Topline Results from EMPOWUR Phase 3 Study in Overactive Bladder

NEW YORK and BASEL, Switzerland, March 19, 2019 /PRNewswire/ -- Today Roivant subsidiary Urovant Sciences announced topline results from its Phase 3 EMPOWUR trial of vibegron in patients with overactive bladder. Vibegron achieved statistically significant improvements over placebo on both ...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Estimated Annual Revenue

Estimated Employees

Vivek Ramaswamy's photo - Founder & CEO of Roivant

Founder & CEO

Vivek Ramaswamy

CEO Approval Rating

83/100

Roivant Sciences researches and develops novel therapies for the treatment of neurological, urology and endocrine diseas... Read more